181 related articles for article (PubMed ID: 30550295)
41. Demonstrating disease activity in patients with rheumatoid arthritis. Is 18F FDG PET a sensitive method?
Karapolat I; Sertpoyraz F; Oncel G; Kobak S; Yalcin M; Kumanlioglu K
Nuklearmedizin; 2013 Dec; 52(6):244-9. PubMed ID: 24081426
[TBL] [Abstract][Full Text] [Related]
42. Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis.
Zheng F; Put S; Bouwens L; Lahoutte T; Matthys P; Muyldermans S; De Baetselier P; Devoogdt N; Raes G; Schoonooghe S
J Nucl Med; 2014 May; 55(5):824-9. PubMed ID: 24686780
[TBL] [Abstract][Full Text] [Related]
43. Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [¹⁸F]-IL1RA and PET imaging in rats.
Cawthorne C; Prenant C; Smigova A; Julyan P; Maroy R; Herholz K; Rothwell N; Boutin H
Br J Pharmacol; 2011 Feb; 162(3):659-72. PubMed ID: 20942812
[TBL] [Abstract][Full Text] [Related]
44. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha.
Baeten D; Van Damme N; Van den Bosch F; Kruithof E; De Vos M; Mielants H; Veys EM; De Keyser F
Ann Rheum Dis; 2001 Aug; 60(8):750-5. PubMed ID: 11454638
[TBL] [Abstract][Full Text] [Related]
45. Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys.
Saito M; Yoshigae Y; Nakayama J; Ogawa Y; Ohtsuki M; Kurihara A; Ikeda T
Life Sci; 2007 May; 80(22):2005-14. PubMed ID: 17477938
[TBL] [Abstract][Full Text] [Related]
46. Aberrant expression of interleukin-10 in rheumatoid arthritis: Relationship with IL10 haplotypes and autoantibodies.
Hernández-Bello J; Oregón-Romero E; Vázquez-Villamar M; García-Arellano S; Valle Y; Padilla-Gutiérrez JR; Román-Fernández IV; Palafox-Sánchez CA; Martínez-Bonilla GE; Muñoz-Valle JF
Cytokine; 2017 Jul; 95():88-96. PubMed ID: 28254559
[TBL] [Abstract][Full Text] [Related]
47. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.
van der Laken CJ; Voskuyl AE; Roos JC; Stigter van Walsum M; de Groot ER; Wolbink G; Dijkmans BA; Aarden LA
Ann Rheum Dis; 2007 Feb; 66(2):253-6. PubMed ID: 16793840
[TBL] [Abstract][Full Text] [Related]
48. Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin.
Rossin R; Berndorff D; Friebe M; Dinkelborg LM; Welch MJ
J Nucl Med; 2007 Jul; 48(7):1172-9. PubMed ID: 17574989
[TBL] [Abstract][Full Text] [Related]
49. (18)F-FDG-PET assessment of early treatment response of articular and extra-articular foci in newly diagnosed rheumatoid arthritis.
Sarma M; Vijayant V; Basu S
Hell J Nucl Med; 2012; 15(1):70-1. PubMed ID: 22413120
[No Abstract] [Full Text] [Related]
50. Comparison of the Accuracy of FMT/CT and PET/MRI for the Assessment of Antibody Biodistribution in Squamous Cell Carcinoma Xenografts.
Hage C; Gremse F; Griessinger CM; Maurer A; Hoffmann SHL; Osl F; Pichler BJ; Kiessling F; Scheuer W; Pöschinger T
J Nucl Med; 2018 Jan; 59(1):44-50. PubMed ID: 28848038
[TBL] [Abstract][Full Text] [Related]
51. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
[TBL] [Abstract][Full Text] [Related]
52. New biologics for rheumatoid arthritis.
Choy E
J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
[TBL] [Abstract][Full Text] [Related]
53. Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis.
Broeren MG; de Vries M; Bennink MB; Arntz OJ; Blom AB; Koenders MI; van Lent PL; van der Kraan PM; van den Berg WB; van de Loo FA
Hum Gene Ther; 2016 Mar; 27(3):244-54. PubMed ID: 26711533
[TBL] [Abstract][Full Text] [Related]
54. Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study.
Bernelot Moens SJ; van der Valk FM; Strang AC; Kroon J; Smits LP; Kneepkens EL; Verberne HJ; van Buul JD; Nurmohamed MT; Stroes ES
Arthritis Res Ther; 2016 May; 18(1):115. PubMed ID: 27209093
[TBL] [Abstract][Full Text] [Related]
55. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.
Choy EHS; Calabrese LH
Rheumatology (Oxford); 2018 Nov; 57(11):1885-1895. PubMed ID: 29186541
[TBL] [Abstract][Full Text] [Related]
56. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
Schmid AS; Tintor D; Neri D
J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
[TBL] [Abstract][Full Text] [Related]
57. A quantitative evaluation of rheumatoid arthritic activity with Tc-99m HEDP.
Park HM; Terman SA; Ridolfo AS; Wellman HN
J Nucl Med; 1977 Oct; 18(10):973-6. PubMed ID: 409749
[TBL] [Abstract][Full Text] [Related]
58. 99mTc-NTP 15-5 Imaging for Cartilage Involvement in Experimental Rheumatoid Arthritis: Comparison with Routinely Used Molecular Imaging Methods and Sensitivity to Chronic Nonsteroidal Antiinflammatory Drug Treatment.
Khairnar A; Marchand F; Vidal A; Etienne M; Miladi I; Auzeloux P; Cachin F; Eschalier A; Chezal JM; Ardid D; Miot-Noirault E
J Nucl Med; 2015 May; 56(5):798-804. PubMed ID: 25840975
[TBL] [Abstract][Full Text] [Related]
59. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure.
Møller Døhn U; Boonen A; Hetland ML; Hansen MS; Knudsen LS; Hansen A; Madsen OR; Hasselquist M; Møller JM; Østergaard M
Ann Rheum Dis; 2009 Oct; 68(10):1585-90. PubMed ID: 19019887
[TBL] [Abstract][Full Text] [Related]
60. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis.
Goerres GW; Forster A; Uebelhart D; Seifert B; Treyer V; Michel B; von Schulthess GK; Kaim AH
Clin Nucl Med; 2006 Jul; 31(7):386-90. PubMed ID: 16785804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
